Poster with the title "From Modest to Meaningful: Targeting TNFR2 with BI-1808 to Unlock Checkpoint Inhibitor Efficacy in ...
A new synthesis in PLOS Neglected Tropical Diseases shows how molecular advances in chromoblastomycosis have failed to ...
A two-year follow-up of 108 mucormycosis patients in Central India reveals heavy antifungal and antibiotic prescribing, ...
Poster with the title "From Modest to Meaningful: Targeting TNFR2 with BI-1808 to Unlock Checkpoint Inhibitor Efficacy in Platinum-Resistant Recurrent Ovarian Cancer ...
BI-1808 monotherapy demonstrated an excellent safety profile and evidence of single-agent anti-tumor activity, correlating ...
Mogamulizumab (Poteligeo) was associated with durable real-world treatment outcomes in patients with mycosis fungoides (MF) ...
Targeting TNFR2 with BI-1808 to Unlock Checkpoint Inhibitor Efficacy in Platinum-Resistant Recurrent Ovarian Cancer (PRROC)" to be presented at ESMO on October 24 The abstract was published today on ...
Kyowa Kirin International has announced final results from the German MINT study evaluating mogamulizumab in patients with MF ...
Publication in the Journal of Bone and Mineral Research offers new insight into the long-term XLH treatment experience PRINCETON, N.J., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Kyowa Kirin, Inc., a wholly ow ...
Phase 2a PTX-100 trial enrolment increased from 1 patient at the start of FY2026 to 26 by 30 June 2026, reaching 29 patients ...
BI-1808 monotherapy demonstrated an excellent safety profile and evidence of single-agent anti-tumor activity, correlating with tumor-infiltrating CD8+ T cells and inducing antitumor immunity.Translat ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results